SPY396.92+7.29 1.87%
DIA318.84+6.42 2.05%
IXIC11,535.28+180.66 1.59%

BRIEF-Adverum Presents Additional Efficacy And Safety Data From Optic Trial Of ADVM-022 In Wet AMD

reuters.com · 05/01/2022 14:20
BRIEF-Adverum Presents Additional Efficacy And Safety Data From Optic Trial Of ADVM-022 In Wet AMD

- Adverum Biotechnologies Inc ADVM:

  • PRESENTS ADDITIONAL EFFICACY AND SAFETY DATA FROM OPTIC TRIAL OF ADVM-022 IN WET AMD

  • ADVERUM - REDUCTIONS IN MEAN ANNUALIZED ANTI-VEGF INJECTIONS RANGED FROM 81% IN ALL PATIENTS TO 94% IN THOSE WITH NABS <1:125 AT 2 X 10^11 VG/EYE

Source text for Eikon: ID:nGNX4xDTrZ

Further company coverage: ADVM


((Reuters.Briefs@thomsonreuters.com;))